Alpha Wave
Funding rounds backed by Alpha Wave.
- Funding disclosed in full
- $315M
- Median round
- $315M
- Rounds in calculation
- 1
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| AdvanCell Develops lead-212 targeted alpha therapies to treat cancer | $315MSeries D | BiotechAustralia | 19 participantsAbingworthAlly Bridge GroupAlpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital |